Peripheral Vascular Devices – Market Insights – Japan

Through 2033, Japanese PV device market growth will be driven by increased adoption of endovascular techniques, along with rising adoption of premium-priced devices such as DCBs and DES. However, revenue growth will be somewhat restricted by ASP declines resulting from the MHLW‘s biennial reimbursement cuts throughout the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in Japan from 2019 through 2033.

The expansion of DES and DCB markets will be driven by new device launches and positive clinical data.

What findings from ongoing and completed trials will contribute to growing use of DES and DCBs in Japan?

To what degree will DES and DCBs be adopted in Japan over the forecast period?

What strategies are competitors employing to capture sales in the growing markets for DCB and DES in Japan?

Advancements in endovascular interventions are primarily concentrating on the treatment of lower extremity conditions.

What upcoming advancements are expected in the PV device market?

How are global clinical developments influencing the Japanese PV device market?

What new devices have been launched or are anticipated to be launched in Japan?

How will the introduction of IVL impact the Japanese PV device market?

How the expansion of IVUS for PV interventions impact market growth? Who are the competitors in this growing segment?

M&A activities or partnerships involving key competitors may lead to shifts in market shares going forward.

Which acquisitions have occurred, and how will these acquisitions impact competitor performance in the future?

How are competitors leveraging product portfolio acquisitions to expand their product offerings?